

ENZO BIOCHEM INC  
Form 10-Q  
December 12, 2011

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
  
FORM 10-Q

Mark one

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended October 31, 2011

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_  
Commission File Number 001-09974

**ENZO BIOCHEM, INC.**

(Exact name of registrant as specified in its charter)

|  |  |
|--|--|
| New York   | 13-2866202                                     |
| _____<br>(State or Other Jurisdiction<br>of Incorporation or Organization) | _____<br>(IRS. Employer<br>Identification No.) |
| 527 Madison Ave, New York, New York  | 10022  |
| _____<br>(Address of Principal Executive office)                           | _____<br>(Zip Code)                            |
| 212-583-0100   |  |
| _____<br>(Registrant's telephone number, including area code)              |  |

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant has required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 45 of Regulation S-T (§232.405 of that chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files).

Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company   
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)

Yes  No

As of December 1, 2011 the Registrant had approximately 38,599,173 shares of common stock outstanding.

---

Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

ENZO BIOCHEM, INC.  
FORM 10-Q  
October 31, 2011

INDEX

PART I - FINANCIAL INFORMATION

|                |   |    |
|----------------|---|----|
| <u>Item 1.</u> | <u>Financial Statements</u>   |    |
|                | <u>Consolidated Balance Sheets - October 31, 2011 (unaudited) and July 31, 2011 (audited)</u>   | 3  |
|                | <u>Consolidated Statements of Operations for the three months ended October 31, 2011 and 2010 (unaudited)</u>                                 | 4  |
|                | <u>Consolidated Statement of Stockholders' Equity and Comprehensive Income (Loss) for the three months ended October 31, 2011 (unaudited)</u> | 5  |
|                | <u>Consolidated Statements of Cash Flows for the three months ended October 31, 2011 and 2010 (unaudited)</u>                                 | 6  |
|                | <u>Notes to Consolidated Financial Statements</u>   | 7  |
| <u>Item 2.</u> | <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>  | 15 |
| <u>Item 3.</u> | <u>Quantitative and Qualitative Disclosures About Market Risk</u>   | 25 |
| <u>Item 4.</u> | <u>Controls and Procedures</u>  | 25 |

Part II - OTHER INFORMATION

|                   |                          |    |
|-------------------|--------------------------|----|
| <u>Item 1.</u>    | <u>Legal Proceedings</u> | 26 |
| <u>Item 1A.</u>   | <u>Risk Factors</u>      | 26 |
| <u>Item 6.</u>    | <u>Exhibits</u>          | 26 |
| <u>Signatures</u> |                          | 26 |

**Part 1** Financial Information  
**Item 1** Financial Statements

**ENZO BIOCHEM, INC.**  
**CONSOLIDATED BALANCE SHEETS**  
(Dollars in thousands, except share data)

|  | <b>October 31,<br/>2011<br/>(unaudited)</b> | <b>July 31,<br/>2011<br/>(audited)</b> |
|--|---|--|
|  | <u>          </u>                           | <u>          </u>                      |
| <b>ASSETS</b>  |   |  |
| Current assets:  |   |  |
| Cash and cash equivalents  | \$ 11,377                                   | \$ 14,161                              |
| Short term investments   | 10,000                                      | 10,000                                 |
| Accounts receivable, net of allowances   | 14,671                                      | 15,245                                 |
| Inventories  | 9,224                                       | 9,260                                  |
| Prepaid expenses   | 2,329                                       | 2,733                                  |
|  | <u>          </u>                           | <u>          </u>                      |
| Total current assets   | 47,601                                      | 51,399                                 |
| Property, plant and equipment, net   | 9,776                                       | 10,335                                 |
| Goodwill   | 26,912                                      | 27,373                                 |
| Intangible assets, net   | 19,310                                      | 19,985                                 |
| Other  | 355   | 382                                    |
|  | <u>          </u>                           | <u>          </u>                      |
| Total assets   | <u>\$ 103,954</u>                           | <u>\$ 109,474</u>                      |
| <b>LIABILITIES AND STOCKHOLDERS EQUITY</b>   |   |  |
| Current liabilities:   |   |  |
| Accounts payable trade   | \$ 6,526                                    | \$ 7,858                               |
| Accrued liabilities  | 9,387                                       | 8,188                                  |
| Other current liabilities  | 1,650                                       | 1,683                                  |
|  | <u>          </u>                           | <u>          </u>                      |
| Total current liabilities  | 17,563                                      | 17,729                                 |
| Deferred taxes   | 2,811                                       | 2,934                                  |
| Other  | 108   | 96                                     |
| Commitments and contingencies  |   |  |
| Stockholders equity:   |   |  |
| Preferred Stock, \$.01 par value; authorized 25,000,000 shares; no shares issued or outstanding  |   |  |
| Common Stock, \$.01 par value; authorized 75,000,000 shares; shares issued: 39,048,687 at October 31, 2011 and 39,045,837 at July 31, 2011 | 390   | 390                                    |
| Additional paid-in capital   | 306,046                                     | 305,833                                |
| Less treasury stock at cost: 450,014 shares at October 31, 2011 and at July 31, 2011   | (6,387)                                     | (6,387)                                |
| Accumulated deficit  | (219,408)                                   | (214,914)                              |
| Accumulated other comprehensive income   | 2,831                                       | 3,793                                  |
|  | <u>          </u>                           | <u>          </u>                      |
| Total stockholders equity  | 83,472                                      | 88,715                                 |
|  | <u>          </u>                           | <u>          </u>                      |
| Total liabilities and stockholders equity  | <u>\$ 103,954</u>                           | <u>\$ 109,474</u>                      |

The accompanying notes are an integral part of these consolidated financial statements.



**ENZO BIOCHEM, INC.**  
**CONSOLIDATED STATEMENTS OF OPERATIONS**  
**(UNAUDITED)**  
(Dollars in thousands, except per share data)

|   | <b>Three Months Ended</b> |                   |
|---|---------------------------|-------------------|
|   | <b>October 31,</b>        |                   |
|   | <b>2011</b>               | <b>2010</b>       |
|   | <u>          </u>         | <u>          </u> |
| Revenues:                                       |                           |                   |
| Clinical laboratory services                    | \$ 14,187                 | \$ 12,390         |
| Product revenues                                | 9,704                     | 10,184            |
| Royalty and license fee income                  | 1,862                     | 3,078             |
|   | <u>25,753</u>             | <u>25,652</u>     |
| Operating expenses:                             |                           |                   |
| Cost of clinical laboratory services            | 8,814                     | 7,573             |
| Cost of product revenues                        | 5,137                     | 4,606             |
| Research and development                        | 1,625                     | 1,757             |
| Selling, general, and administrative            | 12,385                    | 11,032            |
| Provision for uncollectible accounts receivable | 1,286                     | 1,075             |
| Legal   | 868                       | 696               |
|   | <u>30,115</u>             | <u>26,739</u>     |
| Operating loss                                  | (4,362)                   | (1,087)           |
| Other income (expense):                         |                           |                   |
| Interest  | (2)                       | 5                 |
| Other   | 9                         | 14                |
| Foreign currency gain                           | 29                        | 8                 |
|   | <u>(4,326)</u>            | <u>(1,060)</u>    |
| Loss before income taxes                        | (4,326)                   | (1,060)           |
| Provision for income taxes                      | (168)                     | (62)              |
|   | <u>(4,494)</u>            | <u>(1,122)</u>    |
| Net loss  | \$ (4,494)                | \$ (1,122)        |
| Net loss per common share:                      |                           |                   |
| Basic and diluted                               | \$ (0.12)                 | \$ (0.03)         |
| Weighted average common shares outstanding:     |                           |                   |
| Basic and diluted                               | <u>38,597</u>             | <u>38,160</u>     |

The accompanying notes are an integral part of these consolidated financial statements.

**ENZO BIOCHEM, INC.**  
**CONSOLIDATED STATEMENT OF STOCKHOLDERS EQUITY**  
**AND COMPREHENSIVE INCOME (LOSS)**  
**Three months ended October 31, 2011**  
**(UNAUDITED)**  
**(Dollars in thousands, except share data)**

|  | <i>Common<br/>Stock<br/>Shares</i> | <i>Treasury<br/>Stock<br/>Shares</i> | <i>Common<br/>Stock<br/>Amount</i> | <i>Additional<br/>Paid-in<br/>Capital</i> | <i>Treasury<br/>Stock<br/>Amount</i> | <i>Accumulated<br/>Deficit</i> | <i>Accumulated<br/>Other<br/>Comprehensive<br/>Income</i> | <i>Total<br/>Stockholder<br/>Equity</i> | <i>Comprehensive<br/>loss</i> |
|--|------------------------------------|--------------------------------------|------------------------------------|---|--------------------------------------|--------------------------------|---|---|-------------------------------|
| Balance at July 31, 2011                       | 39,045,837                         | 450,014                              | \$ 390                             | \$ 305,833                                | \$ (6,387)                           | \$ (214,914)                   | \$ 3,793  | \$ 88,715                               |                               |
| Net loss for the period ended October 31, 2011 |                                    |                                      |                                    |   |                                      | (4,494)                        |   | (4,494)                                 | (4,494)                       |
| Vesting of restricted stock                    | 2,850                              |                                      |                                    |   |                                      |                                |   |   |                               |
| Stock based compensation charges               |                                    |                                      |                                    | 213                                       |                                      |                                |   | 213                                     |                               |
| Foreign currency translation adjustments       |                                    |                                      |                                    |   |                                      |                                | (962)   | (962)                                   | (962)                         |
| Comprehensive loss                             |                                    |                                      |                                    |   |                                      |                                |   |   | \$ (5,456)                    |
| Balance at October 31, 2011                    | 39,048,687                         | 450,014                              | \$ 390                             | \$ 306,046                                | \$ (6,387)                           | \$ (219,408)                   | \$ 2,831  | \$ 83,472                               |                               |

The accompanying notes are an integral part of these consolidated financial statements.

**ENZO BIOCHEM, INC.**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**(UNAUDITED)**  
**(Dollars in thousands)**

|   | <b>Three Months Ended</b> |             |
|---|---------------------------|-------------|
|   | <b>October 31,</b>        |             |
|   | <b>2011</b>               | <b>2010</b> |
| Cash flows from operating activities:                                       |                           |             |
| Net loss  | \$ (4,494)                | \$ (1,122)  |
| Adjustments to reconcile net loss to net cash used in operating activities: |                           |             |
| Depreciation and amortization of property, plant and equipment              | 801                       | 710         |
| Amortization of intangible assets   | 421                       | 378         |
| Provision for uncollectible accounts receivable                             | 1,286                     | 1,075       |
| Income tax benefit  | (34)                      | (32)        |
| Share based compensation charges  | 213                       | 327         |
| Share based 401(k) employer match expense                                   | 130                       | 161         |
| Deferred revenue recognized   |                           | (38)        |
| Foreign currency transaction gain   | (57)                      | (72)        |
| Changes in operating assets and liabilities:                                |                           |             |
| Accounts receivable   | (724)                     | (2,892)     |
| Inventories   | 17                        | (397)       |
| Prepaid expenses  | 402                       | 222         |
| Accounts payable trade  | (1,341)                   | 559         |
| Accrued liabilities   | 1,099                     | (605)       |
| Other current liabilities   | (33)                      | (20)        |
| Other liabilities   | 12                        | (35)        |
| Net cash used in operating activities                                       | (2,302)                   | (1,781)     |
| Cash flows from investing activities:                                       |                           |             |
| Purchases of short term investments   | (10,000)                  | (41,612)    |
| Maturities of short term investments  | 10,000                    | 43,612      |
| Capital expenditures  | (252)                     | (242)       |
| Security deposits and other   | (106)                     | (52)        |
| Net cash (used in) provided by investing activities                         | (358)                     | 1,706       |
| Cash flows from financing activities:                                       |                           |             |
| Installment loan payments   | (33)                      |             |
| Net cash used in financing activities                                       | (33)                      |             |
| Effect of exchange rate changes on cash and cash equivalents                | (91)                      | 68          |
| Decrease in cash and cash equivalents                                       | (2,784)                   | (7)         |
| Cash and cash equivalents - beginning of period                             | 14,161                    | 8,759       |
| Cash and cash equivalents - end of period                                   | \$ 11,377                 | \$ 8,752    |

The accompanying notes are an integral part of these consolidated financial statements.





# Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

## ENZO BIOCHEM, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

As of October 31, 2011  
and for the three months ended  
October 31, 2011 and 2010  
(Unaudited)  
(Dollars in thousands, except share data)

### Note 1 Basis of Presentation

The accompanying consolidated financial statements include the accounts of Enzo Biochem, Inc. and its wholly-owned subsidiaries, Enzo Life Sciences, Enzo Clinical Labs, Enzo Therapeutics and Enzo Realty LLC, collectively referred to as the Company or Companies. The consolidated balance sheet as of October 31, 2011, the consolidated statement of stockholders equity and comprehensive income (loss) for the three months ended October 31, 2011, the consolidated statements of operations and cash flows for the three months ended October 31, 2011 and 2010, are unaudited. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present fairly the financial position and operating results for the interim periods have been made. Certain information and footnote disclosure, normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States, have been condensed or omitted. The consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended July 31, 2011 and notes thereto contained in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission. The consolidated balance sheet at July 31, 2011 has been derived from the audited financial statements at that date. The results of operations for the three months ended October 31, 2011 are not necessarily indicative of the results that may be expected for the fiscal year ending July 31, 2012.

### *Recent Accounting Pronouncements*

In May 2011, the Financial Accounting Standards Board ( FASB ) issued Accounting Standards Update ( ASU ) No. 2011-04 Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs, which amends the current fair value measurement and disclosure guidance of Accounting Standards Codification ( ASC ) Topic 820 Fair Value Measurement to include increased transparency around valuation inputs and investment categorization. The guidance provided in ASU No. 2011-04 is effective for interim and annual periods beginning after December 15, 2011 and is applied prospectively. The Company does not expect the adoption of these provisions to have a material impact on its consolidated financial statements or on future operating results.

In June 2011, the FASB issued ASU No. 2011-05 Presentation of Comprehensive Income, updating ASC Topic 220, Comprehensive Income. Under the amended ASC Topic 220, an entity has the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. The guidance eliminates the current option to present other comprehensive income and its components in the Statement of Stockholders' Equity. This guidance does not change the components that are recognized in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011, and is to be applied retrospectively. The Company does not believe the adoption of this guidance in the first quarter of fiscal 2013 will have an impact on its consolidated financial statements or on future operating results.

In July 2011, the FASB issued ASU No. 2011-07 Health Care Entities (Topic 954) - Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debts, and the Allowance for Doubtful Accounts for Certain Health Care Entities. This update was issued to provide greater transparency relating to accounting practices used for net patient service revenue and related bad debt allowances by health care entities. Some health care entities recognize patient service revenue at the time the services are rendered regardless of whether the entity expects to collect that amount or has assessed the patient's ability to pay. These prior accounting practices used by some health care entities resulted in a gross-up of patient service revenue and the provision for bad debts, causing difficulty for outside users of financial statements to make accurate comparisons and analyses of financial statements among entities. ASU No. 2011-07 requires certain healthcare entities to change the presentation of the statement of operations, reclassifying the provision for bad debts associated with patient service revenue from an operating expense to a deduction from patient service revenue and also requires enhanced quantitative and qualitative disclosures relevant to the entity's policies for recognizing revenue and assessing bad debts. This update is not designed to change and will not change the net income reported by healthcare entities. This update is effective for fiscal years beginning after December 15, 2011, with early adoption permitted. The Company is currently evaluating the impact the update will have on the presentation of its statement of operations.



## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

In September 2011, the FASB issued ASU No. 2011-08 Intangibles Goodwill and Other (Topic 350) Testing Goodwill for Impairment . The update simplifies how a company tests goodwill for impairment by allowing both public and nonpublic entities the option to first assess qualitative factors to determine whether it is necessary to perform the two-step quantitative goodwill impairment test. Under that option, an entity would no longer be required to calculate the fair value of a reporting unit unless the entity determines, based on a qualitative assessment, that it is more likely than not that its fair value is less than its carrying amount. The update is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011. Early adoption is permitted. The Company does not anticipate that the adoption of this update will have a material impact on its consolidated financial statements.

### *Reclassifications*

Certain amounts in prior years have been reclassified to conform to current year presentation.

### Note 2 Short-term Investments

At October 31, 2011 and July 31, 2011, the Company's short-term investments, whose fair value approximates cost, are in U.S. Treasury bills, which are purchased at discounts with remaining maturities of under ninety days.

The authoritative guidance for fair value measurements establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of the fair value hierarchy under the guidance are described below:

*Level 1:* Valuations based on quoted market prices in active markets for identical assets or liabilities.

*Level 2:* Valuations based on quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities

*Level 3:* Valuations based on inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities

At October 31, 2011 and July 31, 2011 the Company's short-term investments are classified as Level 1 assets.

Note 3 Net loss per share

Basic net income (loss) per share represents net income (loss) divided by the weighted average number of common shares outstanding during the period. The dilutive effect of potential common shares, consisting of outstanding stock options and unvested restricted stock, is determined using the treasury stock method. Diluted weighted average shares outstanding for the three months ended October 31, 2011 and 2010 do not include the potential common shares from stock options and unvested restricted stock because to do so would have been antidilutive. Accordingly, basic and diluted net loss per share is the same during these periods.

During the three months ended October 31, 2011 and 2010 the potential number of shares issued from exercise of in the money stock options, net of shares repurchased with the option exercise proceeds and the potential shares from restricted stock awards was 0 and 66,000, respectively, which are excluded from the computation of diluted net loss per share.. For the three months ended October 31, 2011 and 2010, the effect of approximately 785,000 and 1,075,000 respectively, of outstanding out of the money options to purchase common shares were excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive.

Note 4 Share-based compensation

The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statements of operations:

|                                      | <b>Three months ended<br/>October 31,</b> |               |
|--------------------------------------|---|---------------|
|                                      | <b>2011</b>                               | <b>2010</b>   |
| Cost of clinical laboratory services | \$ 2                                      | \$ 3          |
| Research and development             | 3   | 3             |
| Selling, general and administrative  | 208                                       | 321           |
|                                      | <u>\$ 213</u>                             | <u>\$ 327</u> |

No excess tax benefits were recognized during the three month periods ended October 31, 2011 and 2010.

*Stock option plans*

A summary of the activity relating to the Company's stock option plans for the three month period ended October 31, 2011 is as follows:

|  | <u>Options</u> | <u>Weighted<br/>Average<br/>Exercise Price</u> | <u>Aggregate<br/>Intrinsic<br/>Value</u> |
|--|----------------|--|--|
| Outstanding at August 1, 2011                | 785,124        | \$ 14.53                                       | \$                                       |
| Exercised                                    |                |  |  |
| Cancelled                                    |                | \$   |  |
| Outstanding and exercisable at end of period | <u>785,124</u> | \$ 14.53                                       | <u>\$</u>                                |

As of October 31, 2011, there was no unrecognized compensation cost related to unvested stock option-based compensation.

*Restricted Stock Awards*

A summary of the activity pursuant to the Company's restricted stock awards for the three months ended October 31, 2011 is as follows:

|                            | <u>Awards</u>  | <u>Weighted<br/>Average<br/>Award Price</u> |
|----------------------------|----------------|---|
| Unvested at August 1, 2011 | 311,952        | \$ 4.84                                     |
| Awarded                    |                | \$  |
| Vested                     | (2,850)        | \$ 10.07                                    |
| Forfeited                  | (3,250)        | \$ 4.28                                     |
|                            | <u>305,852</u> | <u>\$ 4.80</u>                              |
| Unvested at end of period  | 305,852        | \$ 4.80                                     |

The fair value of a restricted stock award is determined based on the closing stock price on the award date. As of October 31, 2011, there was approximately \$0.8 million of unrecognized compensation cost related to unvested restricted stock-based compensation to be recognized over a weighted average remaining period of one year.

Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

The total number of shares available for grant as stock options or award as restricted stock is approximately 2,821,000 as of October 31, 2011.

Note 5 Supplemental disclosure for statement of cash flows

Supplemental information with respect to the Company's consolidated statements of cash flows is as follows:

|                | <b>Three months ended<br/>October 31,</b> |             |
|----------------|---|-------------|
|                | <b>2011</b>                               | <b>2010</b> |
| Taxes paid net | \$ 52                                     | \$ 30       |

Note 6 Comprehensive loss and Accumulated Other Comprehensive Income

During the three months ended October 31, 2011 and 2010, total comprehensive loss was approximately \$5.5 million and \$0.4 million, respectively. At October 31, 2011 and July 31, 2011, the accumulated other comprehensive income relates to foreign currency translation adjustments.

Note 7- Inventories

Inventories consist of the following as of:

|                   | <b>October 31,<br/>2011</b> | <b>July 31,<br/>2011</b> |
|-------------------|-----------------------------|--------------------------|
| Raw materials     | \$ 1,114                    | \$ 1,063                 |
| Work in process   | 2,506                       | 2,517                    |
| Finished products | 5,604                       | 5,680                    |
|                   | <b>\$ 9,224</b>             | <b>\$ 9,260</b>          |

Note 8 Goodwill and intangible assets

The Company's change in the net carrying amount of goodwill by business segment is as follows:

|                              | <b>Enzo Life<br/>Sciences</b> | <b>Enzo<br/>Clinical<br/>Labs</b> | <b>Total</b>     |
|------------------------------|-------------------------------|-----------------------------------|------------------|
| Balance August 1, 2011       | \$ 19,921                     | \$ 7,452                          | \$ 27,373        |
| Foreign currency translation | (461)                         |                                   | (461)            |
| Balance October 31, 2011     | <b>\$ 19,460</b>              | <b>\$ 7,452</b>                   | <b>\$ 26,912</b> |

Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

Intangible assets, all of which are included in the Life Sciences segment, consist of the following:

|                                       | October 31, 2011 |                          |           | July 31, 2011 |                          |           |
|---------------------------------------|------------------|--------------------------|-----------|---------------|--------------------------|-----------|
|                                       | Gross            | Accumulated Amortization | Net       | Gross         | Accumulated Amortization | Net       |
| Finite-lived intangible assets:       |                  |                          |           |               |                          |           |
| Patents                               | \$ 11,027        | \$ (10,309)              | \$ 718    | \$ 11,027     | (10,278)                 | \$ 749    |
| Customer relationships                | 12,681           | (3,717)                  | 8,964     | 12,789        | (3,472)                  | 9,317     |
| Website and acquired content          | 1,043            | (776)                    | 267       | 1,063         | (748)                    | 315       |
| Licensed technology and other         | 540              | (275)                    | 265       | 649           | (355)                    | 294       |
| Indefinitely-lived intangible assets: |                  |                          |           |               |                          |           |
| Trademarks                            | 9,096            |                          | 9,096     | 9,310         |                          | 9,310     |
| Total                                 | \$ 34,387        | \$ (15,077)              | \$ 19,310 | \$ 34,838     | \$ (14,853)              | \$ 19,985 |

At October 31, 2011, the weighted average useful life of finite-lived intangible assets was approximately eight years.

For financial reporting purposes, useful lives for intangibles acquired in the Life Sciences acquisitions have been assigned as follows:

|                        |            |
|------------------------|------------|
| Customer relationships | 5-15 years |
| Trademarks             | Indefinite |
| Other intangibles      | 4-5 years  |

Note 9 Accrued Liabilities and Other Current Liabilities

Accrued liabilities consist of the following as of:

|                                    | October 31, 2011 | July 31, 2011 |
|------------------------------------|------------------|---------------|
| Legal                              | \$ 1,131         | \$ 610        |
| Payroll, benefits, and commissions | 4,448            | 4,286         |
| Research and development           | 709              | 709           |
| Professional fees                  | 981              | 782           |
| Other                              | 2,118            | 1,801         |
|                                    | \$ 9,387         | \$ 8,188      |

Other current liabilities consist of the following as of:

|  | October 31, 2011 | July 31, 2011 |
|--|------------------|---------------|
| Liability for purchase price consideration (see Note 13) | 1,150            | 1,150         |
| Deferred revenue   | 347              | 396           |
| Other  | 153              | 137           |
|  | \$ 1,650         | \$ 1,683      |



Note 10 - Income taxes

At the end of each interim reporting period, the Company estimates its effective income tax rate expected to be applicable for the full year. This estimate is used to determine the income tax provision or benefit on a year-to-date basis and may change in subsequent interim periods.

The Company's effective tax rate for the three months ended October 31, 2011 was 3.9% compared to 5.8% during the three months ended October 31, 2010. The tax provision for the periods were based on state and local taxes, domestic and foreign tax for tax deductible goodwill and indefinite lived intangibles, and book to tax differences for inventory.

The Company's effective tax rate for both periods differed from the expected net operating loss carryforward benefit at the U.S. federal statutory rate of 34% primarily due to the inability to recognize such benefit. The carryforward benefit cannot be recognized because of uncertainties relating to future taxable income in terms of both its timing and its sufficiency, which would enable the Company to realize the federal carryforward benefit.

The Company files a consolidated Federal income tax return. The Company files combined returns with California and New York State and City for certain subsidiaries. Other subsidiaries file separate state and foreign tax returns. With few exceptions, the periods that remain subject to examination are fiscal years ended July 31, 2008 through fiscal 2010.

Note 11 Royalty and licensing income

The Company has a license agreement with QIAGEN Gaithersburg Inc. ( QIAGEN ) that began in 2005, whereby the Company earns quarterly running royalties on the net sales of QIAGEN products subject to the license until the expiration of the patent on April 24, 2018. During the three months ended October 31, 2011 and 2010, the Company recorded royalty income under the Agreement of approximately \$1.9 million and \$2.5 million, respectively, which is included in the Life Sciences segment.

On April 27, 2007 (the Effective Date ) Enzo Life Sciences, Inc. ( Life Sciences ) and Abbott Molecular Inc. ( Abbott ) entered into a 5 year agreement, which is still in effect, covering the supply of certain of Enzo Life Sciences products to Abbott for use in their product line. The parties also entered into a limited non-exclusive royalty bearing cross-licensing agreement ( Licensing Agreement ) for various patents. The Licensing Agreement requires each party to pay royalties, as defined through the lives of the related non-expired patents. Abbott has notified the Company that they have made a final royalty payment because they are unaware of any non-expired patents. The Company is presently reviewing its patent portfolio and Abbott's position. The Licensing Agreement between the parties remains in full force and effect and the Company continues its commercialization efforts under the contract terms. During the three months ended October 31, 2010, the Company recorded approximately \$0.5 million in royalties and license fee income under the Licensing Agreement.

Note 12 Segment reporting

The Company has three reportable segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment provides diagnostic services to the health care community. The Company's Life Sciences segment develops, manufactures, and markets products to research and pharmaceutical customers. The Company's Therapeutic segment conducts research and development activities for therapeutic drug candidates. The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as Other , consist of corporate general and administrative costs which are not allocable to the three reportable segments.

Management of the Company assesses assets on a consolidated basis only and, therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies.

Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended October 31, 2011

|  | <u>Clinical<br/>Labs</u> | <u>Life<br/>Sciences</u> | <u>Therapeutics</u> | <u>Other</u>      | <u>Consolidated</u> |
|--|--------------------------|--------------------------|---------------------|-------------------|---------------------|
| <u>Revenues:</u>                                       |                          |                          |                     |                   |                     |
| Clinical laboratory services                           | \$ 14,187                |                          |                     |                   | \$ 14,187           |
| Product revenues                                       |                          | \$ 9,704                 |                     |                   | 9,704               |
| Royalty and license fee income                         |                          | 1,862                    |                     |                   | 1,862               |
|  | <u>14,187</u>            | <u>11,566</u>            |                     |                   | <u>25,753</u>       |
| <u>Operating expenses:</u>                             |                          |                          |                     |                   |                     |
| Cost of clinical laboratory services                   | 8,814                    |                          |                     |                   | 8,814               |
| Cost of product revenues                               |                          | 5,137                    |                     |                   | 5,137               |
| Research and development                               | 44                       | 1,048                    | \$ 533              |                   | 1,625               |
| Selling, general and administrative                    | 4,831                    | 5,228                    |                     | \$ 2,326          | 12,385              |
| Provision for uncollectible accounts<br>receivable     | 1,273                    | 13                       |                     |                   | 1,286               |
| Legal  | 43                       | 383                      |                     | 442               | 868                 |
|  | <u>15,005</u>            | <u>11,809</u>            | <u>533</u>          | <u>2,768</u>      | <u>30,115</u>       |
| Operating loss   | (818)                    | (243)                    | (533)               | (2,768)           | (4,362)             |
| <u>Other income (expense)</u>                          |                          |                          |                     |                   |                     |
| Interest   | (1)                      | (1)                      |                     |                   | (2)                 |
| Other  | 5                        | (5)                      |                     | 9                 | 9                   |
| Foreign exchange gain                                  |                          | 29                       |                     |                   | 29                  |
|  | <u>\$ (814)</u>          | <u>\$ (220)</u>          | <u>\$ (533)</u>     | <u>\$ (2,759)</u> | <u>\$ (4,326)</u>   |
| Depreciation and amortization included<br>above        | \$ 266                   | \$ 914                   | \$ 11               | \$ 31             | \$ 1,222            |
| <u>Share-based compensation included in<br/>above:</u> |                          |                          |                     |                   |                     |
| Cost of clinical laboratory services                   | \$ 2                     |                          |                     |                   | \$ 2                |
| Research and development                               |                          | \$ 3                     |                     |                   | 3                   |
| Selling, general and administrative                    | 13                       | 20                       |                     | \$ 175            | 208                 |
|  | <u>\$ 15</u>             | <u>\$ 23</u>             |                     | <u>\$ 175</u>     | <u>\$ 213</u>       |
| Capital expenditures                                   | \$ 215                   | \$ 30                    |                     | \$ 7              | \$ 252              |

Three months ended October 31, 2010

|  | <u>Clinical<br/>Labs</u> | <u>Life<br/>Sciences</u> | <u>Therapeutics</u> | <u>Other</u>   | <u>Consolidated</u> |
|--|--------------------------|--------------------------|---------------------|----------------|---------------------|
| <b>Revenues:</b>                                   |                          |                          |                     |                |                     |
| Clinical laboratory services                       | \$ 12,390                |                          |                     |                | \$ 12,390           |
| Product revenues                                   |                          | \$ 10,184                |                     |                | 10,184              |
| Royalty and license fee income                     |                          | 3,078                    |                     |                | 3,078               |
|  | <u>12,390</u>            | <u>13,262</u>            |                     |                | <u>25,652</u>       |
| <b>Operating expenses:</b>                         |                          |                          |                     |                |                     |
| Cost of clinical laboratory services               | 7,573                    |                          |                     |                | 7,573               |
| Cost of product revenues                           |                          | 4,606                    |                     |                | 4,606               |
| Research and development                           |                          | 1,265                    | \$ 492              |                | 1,757               |
| Selling, general and administrative                | 4,519                    | 4,248                    |                     | \$ 2,265       | 11,032              |
| Provision for uncollectible accounts receivable    | 1,075                    |                          |                     |                | 1,075               |
| Legal  | 90                       | 99                       |                     | 507            | 696                 |
|  | <u>13,257</u>            | <u>10,218</u>            | <u>492</u>          | <u>2,772</u>   | <u>26,739</u>       |
| Operating income (loss)                            | (867)                    | 3,044                    | (492)               | (2,772)        | (1,087)             |
| <b>Other income (expense)</b>                      |                          |                          |                     |                |                     |
| Interest   |                          |                          |                     | 5              | 5                   |
| Other  | 3                        | 3                        |                     | 8              | 14                  |
| Foreign exchange gain                              |                          | 8                        |                     |                | 8                   |
|  | <u>(864)</u>             | <u>3,055</u>             | <u>(492)</u>        | <u>(2,759)</u> | <u>(1,060)</u>      |
| Income (loss) before income taxes                  | \$ (864)                 | \$ 3,055                 | \$ (492)            | \$ (2,759)     | \$ (1,060)          |
| Depreciation and amortization included above       | \$ 249                   | \$ 795                   | \$ 12               | \$ 32          | \$ 1,088            |
| <b>Share-based compensation included in above:</b> |                          |                          |                     |                |                     |
| Cost of clinical laboratory services               | \$ 3                     |                          |                     |                | \$ 3                |
| Research and development                           |                          | \$ 3                     |                     |                | 3                   |
| Selling, general and administrative                | 15                       | 26                       |                     | \$ 280         | 321                 |
|  | <u>18</u>                | <u>29</u>                |                     | <u>280</u>     | <u>327</u>          |
| Total  | \$ 18                    | \$ 29                    |                     | \$ 280         | \$ 327              |
| Capital expenditures                               | \$ 129                   | \$ 113                   |                     | \$             | \$ 242              |

Note 13 - Contingencies

On or about September 22, 2010, Mayflower Partners, L.P. f/k/a Biomol International, L.P. ( Mayflower ) filed an action against Enzo Biochem, Inc. and Enzo Life Sciences, Inc. (together Enzo ) in the United States District Court for the Southern District of New York, alleging breach of the stock and asset purchase agreement dated as of May 8, 2008 between Enzo and Mayflower (the Agreement ). Pursuant to the Agreement, the Company acquired the assets of Mayflower, and agreed, among other things, to make certain contingent earn-out payments to Mayflower, accounted for as additional purchase price consideration, if certain performance thresholds were met for each of the two annual periods following the closing. Mayflower alleges that Enzo breached the Agreement by allegedly failing to operate the acquired business in good faith during the second earn-out period and engaging in conduct the primary purpose of which was to avoid making a second earn-out period payment under the Agreement. In addition, Mayflower claims that Enzo breached the Agreement by allegedly failing to provide the documentation appropriate to support the calculation of defined financial criteria for the second earn-out period as required under the Agreement. As part of the litigation, Mayflower moved by Order to Show cause to enjoin the accounting procedure specified under the Agreement. Mayflower s motion was heard by a U.S. District Court Judge on September 27, 2010, who directed that the parties first go forward with the accounting procedure, as provided under the Agreement, before moving further with the litigation. The parties were unable to resolve the dispute through the accounting procedure. On January 27, 2011, Mayflower filed an amended complaint. On February 25, 2011, Enzo filed an answer to the amended complaint and on March 4, 2011 filed an amended counterclaim seeking fees and expense of the suit as provided under the Agreement. As provided under the Agreement, Mayflower s maximum contingent earn-out was \$2.5 million payable in either Enzo common stock or cash. On November 3, 2011, the Company and Mayflower entered into an Earn-Out Dispute Settlement Agreement in which the Company paid \$1.15 million in cash in full settlement of the second and final earn-out under the Agreement. The settlement, which was accrued for at July 31, 2011, was recorded in Goodwill as additional purchase price consideration.

The Company is party to other claims, legal actions, complaints, and contractual disputes that arise in the ordinary course of business. The Company believes that any liability that may ultimately result from the resolution of these matters will not, individually or in the aggregate, have a material adverse effect on its financial position or results of operations.

**Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations**

The following discussion of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes and other information included elsewhere in this Quarterly Report on Form 10-Q.

Forward-Looking Statements

Our disclosure and analysis in this report, including but not limited to the information discussed in this Item 2, contain forward-looking information about our Company s financial results and estimates, business prospects and products in research and development that involve substantial risks and uncertainties. From time to time, we also may provide oral or written forward-looking statements in other materials we release to the public. Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historic or current facts. They use words such as anticipate, estimate, expect, project, intend, plan, believe, will, and other words and terms of similar meaning in connection with any discussion of future operations or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, interest rates, foreign exchange rates, intellectual property matters, the outcome of contingencies, such as legal proceedings, and financial results.

We cannot guarantee that any forward-looking statement will be realized, although we believe we have been prudent in our plans and assumptions. Achievement of future results is subject to risks, uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. As a result, investors are cautioned not to place undue reliance on any of our forward-looking statements. Investors should bear this in mind as they consider forward-looking statements.

## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

We do not assume any obligation to update or revise any forward-looking statement that we make, even if new information becomes available or other events occur in the future. We are also affected by other factors that may be identified from time to time in our filings with the Securities and Exchange Commission, some of which are set forth in Item 1A - Risk Factors in our Form 10-K filing for the 2011 fiscal year. You are advised to consult any further disclosures we make on related subjects in our Forms 10-Q, 8-K and 10-K reports to the Securities and Exchange Commission. Although we have attempted to provide a list of important factors which may affect our business, investors are cautioned that other factors may prove to be important in the future and could affect our operating results. You should understand that it is not possible to predict or identify all such factors or to assess the impact of each factor or combination of factors on our business. Consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties.

### Overview

The Company is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological processes to develop research tools, diagnostics and therapeutics and serves as a provider of test services, including esoteric tests, to the medical community. Since our founding in 1976, our strategic focus has been on the development of enabling technologies in research, development, manufacture, licensing and marketing of innovative health care products, platforms and services based on molecular and cellular technologies. Our pioneering work in genomic analysis coupled with its extensive patent estate and enabling platforms have strategically positioned the Company to play an important role in the rapidly growing life sciences and molecular medicine marketplaces.

We are comprised of three wholly owned operating segments that have evolved out of our core competencies: the use of nucleic acids as informational molecules and the use of compounds for immune modulation. Below are brief descriptions of each of the three operating segments (see Note 12 in the Notes to Consolidated Financial Statements):

**Enzo Clinical Labs** is a regional clinical laboratory serving the greater New York, New Jersey and Eastern Pennsylvania medical communities. The Company believes having clinical diagnostic services allows us to capitalize firsthand on our extensive advanced molecular and cytogenetic capabilities and the broader trends in predictive and personalized diagnostics. We offer a menu of routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, or search for an otherwise undiagnosed condition. We operate a full-service clinical laboratory in Farmingdale, New York, a network of 30 patient service centers throughout greater New York, New Jersey and Eastern Pennsylvania, a stand alone stat or rapid response laboratory in New York City, and a full-service phlebotomy and logistics department.

**Enzo Life Sciences** manufactures, develops and markets functional biology and cellular biochemistry products and tools to life sciences, pharmaceutical and clinical research customers world-wide and has amassed a large patent and technology portfolio. Enzo Life Sciences, Inc. is a recognized leader in labeling and detection technologies across research and diagnostic markets. Our portfolio of proteins, antibodies, peptides, small molecules, labeling probes, dyes and kits provides life science researchers tools for target identification/validation, high content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. We are internationally recognized and acknowledged as a leader in manufacturing, in-licensing, and commercialization of over 9,000 of our own products and in addition distribute over 30,000 products made by over 40 other original manufacturers.

Our strategic focus is directed to innovative high quality research reagents and kits in the primary key research areas of protein homeostasis, epigenetics, live cell analysis, molecular biology and immunoassays. The segment is an established source for a comprehensive panel of products to scientific experts in the fields of Natural Products/Antibiotics, Autophagy, Cancer, Cell Cycle, Cell Death, Cell Signaling, Cellular Analysis, Endocrinology/Hormones, DNA regulation, Compound Screening, Genomics/Molecular Biology, GPCRs, Immunology, Inflammation, Metabolism, Neuroscience, Nitric Oxide pathway, Obesity/Adipokines, Oxidative Stress, Proteases and Proteasomes, Protein Expression and modification, Signal Transduction, Stress/Heat Shock proteins and Ubiquitin/Ubl signaling.

**Enzo Therapeutics** is a biopharmaceutical venture that has developed multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of Enzo Life Sciences. The Company has focused its efforts on developing treatment regimens for diseases and conditions in which current treatment options are ineffective, costly, and/or cause unwanted side effects. This focus has generated a clinical and preclinical pipeline, as well as more than 45 patents and patent applications.

**Results of Operations**  
**Three months ended October 31, 2011 as compared to October 31, 2010**

Comparative Financial Data for the Three Months Ended October 31,

|   | 2011              | 2010              | Increase<br>(Decrease) | %<br>Change  |
|---|-------------------|-------------------|------------------------|--------------|
| <b>Revenues:</b>                                |                   |                   |                        |              |
| Clinical laboratory services                    | \$ 14,187         | \$ 12,390         | \$ 1,797               | 15%          |
| Product revenues                                | 9,704             | 10,184            | (480)                  | (5)          |
| Royalty and license fee income                  | 1,862             | 3,078             | (1,216)                | (40)         |
| <b>Total revenues</b>                           | <b>25,753</b>     | <b>25,652</b>     | <b>101</b>             |              |
| <b>Operating expenses:</b>                      |                   |                   |                        |              |
| Cost of clinical laboratory services            | 8,814             | 7,573             | 1,241                  | 16           |
| Cost of product revenues                        | 5,137             | 4,606             | 531                    | 12           |
| Research and development                        | 1,625             | 1,757             | (132)                  | (8)          |
| Selling, general, and administrative            | 12,385            | 11,032            | 1,353                  | 12           |
| Provision for uncollectible accounts receivable | 1,286             | 1,075             | 211                    | 20           |
| Legal   | 868               | 696               | 172                    | 25           |
| <b>Total operating expenses</b>                 | <b>30,115</b>     | <b>26,739</b>     | <b>3,376</b>           | <b>13</b>    |
| <b>Operating loss</b>                           | <b>(4,362)</b>    | <b>(1,087)</b>    | <b>(3,275)</b>         | <b>(301)</b> |
| <b>Other income (expense):</b>                  |                   |                   |                        |              |
| Interest income                                 | (2)               | 5                 | (7)                    | (140)        |
| Other income                                    | 9                 | 14                | (5)                    | (36)         |
| Foreign currency gain                           | 29                | 8                 | 21                     | 263          |
| <b>Loss before income taxes</b>                 | <b>\$ (4,326)</b> | <b>\$ (1,060)</b> | <b>\$ (3,266)</b>      | <b>(308)</b> |

**Consolidated Results:**

The 2012 period and the 2011 period refer to the three months ended October 31, 2011 and 2010, respectively.

Clinical laboratory revenues during the 2012 period were \$14.2 million compared to \$12.4 million in the 2011 period. The 2012 period's increase over the 2011 period was \$1.8 million or 15% due to organic growth.

Product revenues decreased by \$0.5 million or 5% in the 2012 period to \$9.7 million as compared to the 2011 period due to a decline of \$0.6 million or 6% in organic sales. During the period we experienced a decline attributed to certain distributed products for select customers, declines in resale products due to market softness in academia and relatively flat performance in our core products. The decline is offset by a 1% positive impact from foreign currency transactions.

Royalty and license fee income during the 2012 period was \$1.9 million compared to \$3.1 million in the 2011 period, a decrease of \$1.2 million or 40%. Royalties are primarily earned from the reported sales of Qiagen products subject to a license agreement. During the 2012 period the Qiagen royalties decreased by \$0.7 million as compared to the 2011 period, to \$1.9 million as a result of lower reported sales from Qiagen. Qiagen has reported that it expects the recovery of such lower reported sales in the subsequent period. In addition, the 2012 period decrease is also due to Abbott's notification in the 2011 period that they had made a final payment under a license agreement, which aggregated \$0.5 million, since they were not aware of any non-expired patents covered under the license agreement. Abbott and the Company are in communication as to patents covered under the license agreement which remains in full force. There are no direct expenses relating to royalty and licensing income.

The cost of clinical laboratory services during the 2012 period was \$8.8 million as compared to \$7.6 million in the 2011 period, an increase of \$1.2 million or 16%. The Company incurred increased costs due to higher reagent costs and supplies of \$0.5 million,

## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

higher laboratory personnel costs of \$0.3 million, higher outside reference lab costs of \$0.3 million and related other lab costs of \$0.1 million, all attributed to the increased service volume. In the 2012 period the gross profit margin decreased 1% to 38% due to increases in the above mentioned costs of laboratory services directly attributed to greater service volume and affected by test mix performed.

## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

The cost of product revenues during the 2012 period was \$5.1 million compared to \$4.6 million in the 2011 period, an increase of \$0.5 million or 12%. The increase is primarily due to changes in cost allocations to the costs of production of \$0.2 million, increased payroll due to headcount increases of \$0.1 million, and costs associated with rationalization of a production facility of \$0.1 million.

Research and development expenses were approximately \$1.6 million during the 2012 period, compared to \$1.8 million in the 2011 period, a decrease of \$0.2 million or 8%. The decrease was principally attributed to lower costs of \$0.2 million at Enzo Life Sciences due to lower payroll and overhead costs of \$0.1 million and lower patent related costs of \$0.1 million. The clinical trial and related activities at the Therapeutics segment was comparable to the 2011 period.

Selling, general and administrative expenses were approximately \$12.4 million during the 2012 period as compared to \$11.0 million in the 2011 period, an increase of \$1.4 million or 12%. The Clinical Lab segment's selling general and administrative increased by \$0.3 million primarily due to an increase in sales commissions of \$0.2 million and an increase in other expenses of \$0.2 million both related to the increased revenue volume, offset by a decline in payroll and related benefits of \$0.1 million. The Enzo Life Sciences segment increased by \$1.0 million due to a \$0.8 million increase in compensation costs for existing personnel and for new hires of senior level personnel, an increase in amortization of intangibles and travel approximating \$0.1 million, and other costs of \$0.1 million. The Other segment's selling general and administrative increased by \$0.1 million, primarily due to increased professional fees of \$0.2 million offset by decreases of \$0.1 million in payroll related costs.

The provision for uncollectible accounts receivable, primarily relating to the Clinical Labs segment was \$1.3 million for the 2012 period as compared to \$1.1 million in the 2011 period, an increase of \$0.2 million. As a percentage of revenues the provision for uncollectible accounts increased to 9% in the 2012 period as compared to 8.7% in the 2011 period. The increase is attributed to an additional provision required for a lower collection rate in the current period which is partially affected by payer mix.

Legal expense was \$0.9 million during the 2012 period compared to \$0.7 million in the 2011 period, an increase of \$0.2 million due to overall increases in legal services in the 2012 period for general and litigation related matters.

During the 2012 and 2011 periods, the gain on foreign currency transactions was comparable.



## Segment Results

The Clinical Labs segment's loss before taxes was \$0.8 million for the 2012 period as compared to a loss of \$0.9 million in the 2011 period, an improvement of \$0.1 million resulting from increased service volume. The revenue from laboratory services increased in the 2012 period by \$1.8 million or 15% due to organic growth. The 2012 period gross profit of \$5.4 million increased over the 2011 period by \$0.6 million or 12% due to changes in service revenues and cost of lab services. Selling, general and administrative expense increased by approximately \$0.3 million primarily due to increases in sales commissions directly the result of increased service revenues and other costs associated with the increased volume. The provision for uncollectible accounts receivables increased by \$0.2 million as compared to the 2011 period due to the increase in patient service volume and was 9.0% as a percentage of revenues compared to 8.7% in the 2011 period.

The Life Sciences segment's loss before taxes was \$0.2 million for the 2012 period as compared to income of \$3.1 million for the 2011 period. Product revenues decreased by \$0.5 million or 5% in the 2012 period primarily due to a decline of organic sales of 6% attributed to certain distributed products for select customers and resale products due to market softness in academia and relatively flat performance in our core products. The decline is offset by a 1% positive impact from foreign currency transactions. Further, royalty and license fee income decreased by \$1.2 million in the 2012 period principally attributed a decrease in royalties of \$0.7 million from the reported sales of Qiagen products subject to a license agreement, as previously discussed, and in addition, no royalty payments received under the Abbott license agreement after the first quarter of the 2011 period. The segment's gross profit of \$6.4 million in the 2012 period, as compared \$8.7 million in the 2011 period, was negatively impacted by the previously discussed changes in revenues and an increase of \$0.5 million in cost of product revenues. The segment's other operating expenses, including selling, general and administrative, legal and research and development, increased by approximately \$1.1 million during the 2012 period primarily due to higher compensation to existing personnel and for new hires of senior level personnel and higher legal costs related to litigation matters, offset by reduced research and development expenses.

The Therapeutics segment's loss before income taxes was approximately \$0.5 million for the 2012 period was comparable to the loss for the 2011 period.

The Other segment's loss before taxes for the 2012 period of approximately \$2.8 million was comparable to the loss in the 2011 period. In the 2012 period legal expenses decreased by \$0.1 million due to overall decreases in legal services in general and litigation related matters and payroll related costs decreased by \$0.1 million as compared to the 2011 period, offset by an increase in professional fees of \$0.2 million.

## Liquidity and Capital Resources

At October 31, 2011, the Company had cash and cash equivalents of \$11.4 million and short-term investments of \$10.0 million, or \$21.4 million in aggregate as compared to \$24.2 million at July 31, 2011. Short term investments are in US Government Treasury bills. The Company had working capital of \$30.0 million at October 31, 2011 compared to \$33.7 million at July 31, 2011. The decrease in working capital of \$3.7 million was primarily the result of funding capital expenditures and the period net loss during the 2012 period offset by changes in net operating assets and liabilities.

Net cash used in operating activities for the three months ended October 31, 2011 was approximately \$2.3 million as compared to \$1.8 million for the three months ended October 31, 2010. The increase in net cash used in operating activities in the 2012 period over the 2011 period of approximately \$0.5 million was primarily attributed to the increase in the net loss of \$3.4 million offset by an increase in non-cash adjustments in the 2012 period over the 2011 period of \$0.3 million and changes in operating assets and liabilities of \$2.6 million from the 2011 to 2012 period, primarily relating to accounts receivable, inventory, accounts payable and accrued liabilities.

Net cash used in investing activities was approximately \$0.4 million compared to cash provided by investing activities of \$1.7 million in the year ago period, a decrease of \$2.1 million. The decrease is primarily due the net maturities of short term investments in US Government instruments of \$2.0 million in the 2011 period as compared to \$0.0 million in the 2012 period

Net cash used in financing activities in 2012 was \$0.03 million. There were no financing activities in 2011.

## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

On November 3, 2011, the Company and Mayflower entered into an Earn-Out Dispute Settlement Agreement in which the Company paid \$1.15 million in cash in full settlement of the second and final earn-out under the Agreement. (See Note 13).

The Company believes that its current cash and short-term investment level is sufficient for its foreseeable liquidity and capital resource needs over the next 12 months, although there can be no assurance that future events will not alter such view.

### Contractual Obligations

There have been no material changes to our Contractual Obligations as reported in our Form 10-K for the fiscal year ended July 31, 2011.

Management is not aware of any material claims, disputes or settled matters concerning third party reimbursement that would have a material effect on our financial statements.

### Off Balance Sheet Arrangements

The Company does not have any off balance sheet arrangements as such term is defined in Item 303(a)(4) of Regulation S-K.

### Critical Accounting Policies

The Company's discussion and analysis of its financial condition and results of operations are based upon Enzo Biochem, Inc.'s consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses; these estimates and judgments also affect related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including those related to contractual adjustments, allowance for uncollectible accounts, inventory, intangible assets and income taxes. The Company bases its estimates on experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

#### Product revenues

Revenues from product sales are recognized when the products are shipped and title transfers, the sales price is fixed or determinable and collectibility is reasonably assured.

#### Royalties

Royalty revenues are recorded in the period earned. Royalties received in advance of being earned are recorded as deferred revenues.

#### Revenues - Clinical laboratory services

Revenues from Clinical Labs are recognized upon completion of the testing process for a specific patient and reported to the ordering physician. These revenues and the associated accounts receivable are based on gross amounts billed or billable for services rendered, net of a contractual adjustment, which is the difference between amounts billed to payers and the expected approved reimbursable settlements from such payers.

The following are tables of the Clinical Labs segment's net revenues and percentages by revenue category for the three months ended October 31, 2011 and 2010:

| <u>Revenue category</u> | <u>Three months ended<br/>October 31, 2011</u> |     | <u>Three months ended<br/>October 31, 2010</u> |     |
|-------------------------|--|-----|--|-----|
| Medicare                | \$ 3,020                                       | 21% | \$ 2,779                                       | 22% |
| Third-party payer       | 6,942  | 49  | 5,623  | 45  |
| Patient self-pay        | 2,915  | 21  | 2,689  | 22  |

Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

|       |                  |             |                  |             |
|-------|------------------|-------------|------------------|-------------|
| HMO s | 1,310            | 9           | 1,299            | 11          |
| Total | <u>\$ 14,187</u> | <u>100%</u> | <u>\$ 12,390</u> | <u>100%</u> |

20

---

## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

The Company provides services to certain patients covered by various third-party payers, including the Federal Medicare program. Laws and regulations governing Medicare are complex and subject to interpretation for which action for noncompliance includes fines, penalties and exclusion from the Medicare programs. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing.

Other than the Medicare program, one provider whose programs are included in the Third-party payer and Health Maintenance Organizations ( HMO s ) categories represented 21% and 23% of the Clinical Labs net revenues for the three months ended October 31, 2011 and 2010, respectively. Another provider, whose programs are included in the Third-party payer category represented 13% and 7% of Clinical Labs net revenues for the three months ended October 31, 2011 and 2010, respectively.

### Contractual Adjustment

The Company s estimate of contractual adjustment is based on significant assumptions and judgments, such as its interpretation of payer reimbursement policies, and bears the risk of change. The estimation process is based on the experience of amounts approved as reimbursable and ultimately settled by payers, versus the corresponding gross amount billed to the respective payers. The contractual adjustment is an estimate that reduces gross revenue, based on gross billing rates, to amounts expected to be approved and reimbursed. Gross billings are based on a standard fee schedule we set for all third party payers, including Medicare, HMO s and managed care. The Company adjusts the contractual adjustment estimate quarterly, based on its evaluation of current and historical settlement experience with payers, industry reimbursement trends, and other relevant factors.

The other relevant factors that affect our contractual adjustment include the monthly and quarterly review of: 1) current gross billings and receivables and reimbursement by payer, 2) current changes in third party arrangements, 3) the growth of in-network provider arrangements and managed care plans specific to our Company.

Our clinical laboratory business is primarily dependent upon reimbursement from third-party payers, such as Medicare (which principally serves patients 65 and older) and insurers. We are subject to variances in reimbursement rates among different third-party payers, as well as constant changes of reimbursement rates. Changes that decrease reimbursement rates or coverage would negatively impact our revenues. The number of individuals covered under managed care contracts or other similar arrangements has grown over the past several years and may continue to grow in the future. In addition, Medicare and other government healthcare programs continue to shift to managed care. These trends will continue to reduce our revenues.

During the three months ended October 31, 2011 and 2010, the contractual adjustment percentages, determined using current and historical reimbursement statistics, were 84.5% and 83.7%, respectively, of gross billings. The Company believes the negative impact on revenues from the decline in reimbursement rates or the shift to managed care, other primary third party payers, or similar arrangements may be offset by the positive impact of the number of tests we perform. However, there can be no assurance that we can increase the number of tests we perform or that if we do increase the number of tests we perform, that we can maintain that higher number of tests performed, or that an increase in the number of tests we perform would result in increased revenue.

The Company estimates (by using a sensitivity analysis) that each 1% point change in the contractual adjustment percentage could result in a change in clinical laboratory services revenues of approximately \$0.9 million and \$0.6 million for the three months ended October 31, 2011 and 2010, respectively, and a change in the net accounts receivable of approximately \$0.5 million as of October 31, 2011.

Our clinical laboratory financial billing system records gross billings using a standard fee schedule for all payers and does not record contractual adjustment by payer at the time of billing. Adjustments to our standard fee schedule will impact the contractual adjustment recorded. Therefore, we are unable to quantify the effect of contractual adjustment recorded during the current period that relates to revenue recorded in a previous period. However, we can reasonably estimate our contractual adjustment to revenue on a timely basis based on our quarterly review process, which includes:

an analysis of industry reimbursement trends;

an evaluation of third-party reimbursement rates changes and changes in reimbursement arrangements with third-party payers;

a rolling monthly analysis of current and historical claim settlement and reimbursement experience statistics with payers;

an analysis of current gross billings and receivables by payer.

Accounts Receivable and Allowance for Doubtful Accounts

Accounts receivable are reported at realizable value, net of allowances for doubtful accounts, which is estimated and recorded in the period of the related revenue.

The following is a table of the Company's net accounts receivable by segment. The Clinical Labs segment's net receivables are detailed by billing category and as a percent to its total net receivables. At October 31, 2011 and July 31, 2011, approximately 50% and 51%, respectively, of the Company's net accounts receivable relates to its Clinical Labs business, which operates in the New York, New Jersey, and Eastern Pennsylvania medical communities.

The Life Sciences segment's accounts receivable, of which \$2.2 million or 30% and \$2.5 million or 33% represents foreign receivables as of October 31, 2011 and July 31, 2011 respectively, includes royalty receivables of \$1.9 million and \$2.0 million, as of October 31, 2011 and July 31, 2011, respectively, from Qiagen Corporation (Note 11).

Net accounts receivable

| Billing category          | As of<br>October 31, 2011 |      | As of<br>July 31, 2011 |      |
|---------------------------|---------------------------|------|------------------------|------|
| Clinical Labs             |                           |      |                        |      |
| Medicare                  | \$ 1,252                  | 17%  | \$ 1,434               | 19%  |
| Third party payers        | 2,966                     | 40   | 3,087                  | 40   |
| Patient self-pay          | 2,825                     | 38   | 2,865                  | 37   |
| HMO's                     | 331                       | 5    | 314                    | 4    |
|                           |                           |      |                        |      |
| Total Clinical Labs       | 7,374                     | 100% | 7,700                  | 100% |
|                           |                           |      |                        |      |
| Total Life Sciences       | 7,297                     |      | 7,545                  |      |
|                           |                           |      |                        |      |
| Total accounts receivable | \$ 14,671                 |      | \$ 15,245              |      |
|                           |                           |      |                        |      |

Changes in the Company's allowance for doubtful accounts are as follows:

|                                 | Three months<br>ended<br>October 31,<br>2011 | Twelve<br>months<br>ended<br>July 31,<br>2011 |
|---------------------------------|--|---|
|                                 |  |   |
| Beginning balance               | \$ 3,488                                     | \$ 2,839                                      |
| Provision for doubtful accounts | 1,286  | 4,431   |
| Write-offs, net                 | (920)  | (3,782)                                       |
|                                 |  |   |
| Ending balance                  | \$ 3,854                                     | \$ 3,488                                      |
|                                 |  |   |

For the Clinical Labs segment, the allowance for doubtful accounts represents amounts that the Company does not expect to collect after the Company has exhausted its collection procedures. The Company estimates its allowance for doubtful accounts in the period the related services are billed and adjusts the estimate in future accounting periods as necessary. It bases the estimate for the allowance on the evaluation of historical collection experience, the aging profile of accounts receivable, the historical doubtful account write-off percentages, payer mix, and other relevant factors.

The allowance for doubtful accounts includes the balances, after receipt of the approved settlements from third party payers for the insufficient diagnosis information received from the ordering physician, which result in denials of payment and the uncollectible portion of receivables from self payers, including deductibles and copayments, which are subject to credit risk and patients' ability to pay. During the three months ended October 31, 2011 and 2010, the Company determined an allowance for doubtful accounts less

## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

than 210 days and wrote off 100% of accounts receivable over 210 days, as it assumed those accounts are uncollectible, except for certain fully reserved balances, principally related to Medicare. These accounts have not been written off because the payer's filing date deadline has not occurred or the collection process has not been exhausted. The Company's collection experience on Medicare receivables beyond 210 days has been insignificant. The Company adjusts the historical collection analysis for recoveries, if any, on an ongoing basis.

The Company's ability to collect outstanding receivables from third party payers is critical to its operating performance and cash flows. The primary collection risk lies with uninsured patients or patients for whom primary insurance has paid but a patient portion remains outstanding. The Company also assesses the current state of its billing functions in order to identify any known collection or reimbursement issues in order to assess the impact, if any, on the allowance estimates, which involves judgment.

Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

The Company believes that the collectibility of its receivables is directly linked to the quality of its billing processes, most notably, those related to obtaining the correct information in order to bill effectively for the services provided. Should circumstances change (e.g. shift in payer mix, decline in economic conditions or deterioration in aging of receivables), our estimates of net realizable value of receivables could be reduced by a material amount.

The following table indicates the Clinical Labs aged gross receivables by payer group which is prior to adjustment to gross receivables for: 1) contractual adjustment, 2) fully reserved balances not yet written off, and 3) other revenue adjustments.

| As of October 31, 2011 | Total Amount     | %           | Medicare Amount | %           | Third Party Payers Amount | %           | Self-pay Amount  | %           | HMO Amount      | %           |
|------------------------|------------------|-------------|-----------------|-------------|---------------------------|-------------|------------------|-------------|-----------------|-------------|
| 1-30 days              | \$ 26,624        | 55%         | \$ 5,242        | 58%         | \$ 12,444                 | 52%         | \$ 4,767         | 42%         | \$ 4,171        | 93%         |
| 31-60 days             | 6,346            | 13%         | 683             | 8%          | 3,440                     | 15%         | 2,139            | 18%         | 84              | 2%          |
| 61-90 days             | 5,525            | 11%         | 669             | 7%          | 2,556                     | 11%         | 2,225            | 19%         | 75              | 2%          |
| 91-120 days            | 4,466            | 9%          | 552             | 6%          | 1,989                     | 9%          | 1,857            | 16%         | 68              | 1%          |
| 121-150 days           | 2,233            | 5%          | 495             | 6%          | 1,162                     | 5%          | 528              | 5%          | 48              | 1%          |
| Greater than 150 days* | 3,274            | 7%          | 1,383           | 15%         | 1,787                     | 8%          | 48               | 0%          | 56              | 1%          |
| <b>Totals</b>          | <b>\$ 48,468</b> | <b>100%</b> | <b>\$ 9,024</b> | <b>100%</b> | <b>\$ 23,378</b>          | <b>100%</b> | <b>\$ 11,564</b> | <b>100%</b> | <b>\$ 4,502</b> | <b>100%</b> |

| As of July 31, 2011    | Total Amount     | %           | Medicare Amount | %           | Third Party Payers Amount | %           | Self-pay Amount | %           | HMO s Amount | %           |
|------------------------|------------------|-------------|-----------------|-------------|---------------------------|-------------|-----------------|-------------|--------------|-------------|
| 1-30 days              | \$ 29,880        | 60%         | 5,843           | 60%         | 13,851                    | 56%         | 6,173           | 55%         | 4,013        | 95%         |
| 31-60 days             | 7,013            | 14%         | 791             | 8%          | 3,441                     | 14%         | 2,687           | 24%         | 93           | 2%          |
| 61-90 days             | 4,029            | 8%          | 566             | 6%          | 2,522                     | 10%         | 890             | 8%          | 51           | 1%          |
| 91-120 days            | 3,826            | 8%          | 917             | 9%          | 1,819                     | 7%          | 1,046           | 9%          | 44           | 1%          |
| 121-150 days           | 2,084            | 4%          | 375             | 4%          | 1,385                     | 6%          | 288             | 3%          | 37           | 1%          |
| Greater than 150 days* | 3,050            | 6%          | 1,234           | 13%         | 1,717                     | 7%          | 94              | 1%          | 5            | 0%          |
| <b>Totals</b>          | <b>\$ 49,882</b> | <b>100%</b> | <b>9,726</b>    | <b>100%</b> | <b>24,735</b>             | <b>100%</b> | <b>11,178</b>   | <b>100%</b> | <b>4,243</b> | <b>100%</b> |

\* Total includes \$958 fully reserved over 210 days as of October 31, 2011.

\*\* Total includes \$800 fully reserved over 210 days as of July 31, 2011.

*Income Taxes*

The Company accounts for income taxes under the liability method of accounting for income taxes. Under the liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The liability method requires that any tax benefits recognized for net operating loss carry forwards and other items be reduced by a valuation allowance where it is not more likely than not the benefits will be realized in the foreseeable future.

Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under the liability method, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

*Inventory*

## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

The Company values inventory at the lower of cost (first-in, first-out) or market. Work-in-process and finished goods inventories consist of material, labor, and manufacturing overhead. Write downs of inventories to market value are based on a review of inventory quantities on hand and estimated sales forecasts based on sales history and anticipated future demand. Unanticipated changes in demand could have a significant impact on the value of our inventory and require additional write downs of inventory which would impact our results of operations.

### *Goodwill and Indefinite-Lived Intangibles*

Goodwill, representing the cost of acquired businesses in excess of the fair value of net assets acquired, and indefinite-lived intangibles are not amortized, but are evaluated annually for impairment. The Company performs its annual impairment test as of the first day of its fiscal fourth quarter or if indicators of potential impairment exist. Goodwill is considered impaired if the carrying amount of the reporting unit exceeds its estimated fair value. In assessing the recoverability of goodwill, the Company reviews both quantitative as well as qualitative factors to support its assumptions with regard to fair value.



## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

The fair value of a reporting unit is estimated using both a discounted cash flow model and market approach model. In determining fair value, the Company makes certain judgments on the assumptions included in the discounted cash flow such as forecasted revenue, gross profit margins, working capital cash flow, the identification of reporting units and the selection of comparable companies for the market approach. Trademarks are considered impaired if the carrying amount exceeds their estimated fair value. To date, there has been no impairment charges recorded.

### *Intangible Assets*

Intangible assets (exclusive of patents), arose primarily from acquisitions and primarily consist of customer relationships, trademarks, licenses, employment and non-compete agreements, and website and database content. Finite-lived intangible assets are amortized according to their estimated useful lives, which range from 4 to 15 years. The Company has capitalized certain legal costs directly incurred in pursuing patent applications as patent costs. When such applications result in an issued patent, the related costs are amortized over a ten year period or the life of the patent, whichever is shorter, using the straight-line method. The Company reviews its issued patents and pending patent applications, and if it determines to abandon a patent application or that an issued patent no longer has economic value, the unamortized balance in deferred patent costs relating to that patent is immediately expensed.

### *Accrual for Self-funded Medical*

Accruals for self-funded medical insurance are determined based on a number of assumptions and factors, including historical payment trends, claims history and current estimates. These estimated liabilities are not discounted. If actual trends differ from these estimates, the financial results could be impacted. As of October 31, 2011, the Company has established a reserve of \$0.3 million, which is included in accrued liabilities, for claims that have been reported but not paid and for claims incurred but not reported.

### *Recent Accounting Pronouncements*

In May 2011, the Financial Accounting Standards Board ( FASB ) issued Accounting Standards Update ( ASU ) 2011-04, Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs, which amends the current fair value measurement and disclosure guidance of Accounting Standards Codification ( ASC ) Topic 820 Fair Value Measurement to include increased transparency around valuation inputs and investment categorization. The guidance provided in ASU No. 2011-04 is effective for interim and annual periods beginning after December 15, 2011 and is applied prospectively. The Company does not expect the adoption of these provisions to have a material impact on its consolidated financial statements or on future operating results.

In June 2011, the FASB issued ASU 2011-05, Presentation of Comprehensive Income, updating ASC Topic 220, Comprehensive Income. Under the amended ASC Topic 220, an entity has the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. The guidance eliminates the current option to present other comprehensive income and its components in the Statement of Stockholders' Equity. This guidance does not change the components that are recognized in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011, and is to be applied retrospectively. The Company does not believe the adoption of this guidance in the first quarter of fiscal 2013 will have an impact on its consolidated financial statements or on future operating results.

In July 2011, the FASB issued ASU No. 2011-07: Health Care Entities (Topic 954) Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debts, and the Allowance for Doubtful Accounts for Certain Health Care Entities. This update was issued to provide greater transparency relating to accounting practices used for net patient service revenue and related bad debt allowances by health care entities. Some health care entities recognize patient service revenue at the time the services are rendered regardless of whether the entity expects to collect that amount or has assessed the patient's ability to pay. These prior accounting practices used by some health care entities resulted in a gross-up of patient service revenue and the provision for bad debts, causing difficulty for outside users of financial statements to make accurate comparisons and analyses of financial statements among entities. ASU No. 2011-07 requires certain healthcare entities to change the presentation of the statement of operations, reclassifying the provision for bad debts associated with patient service revenue from an operating expense to a deduction from patient service revenue and also requires enhanced quantitative and qualitative disclosures relevant to the entity's policies for recognizing revenue and assessing bad debts. This update is not designed and will not change the net income reported by healthcare entities. This update is effective for fiscal years beginning after December 15, 2011, with early adoption permitted. The Company does not expect that this update will have any material impact on its consolidated financial statements. The Company is currently evaluating if the update will have any impact on the presentation of its statement of operations.



## Edgar Filing: ENZO BIOCHEM INC - Form 10-Q

In September 2011, the FASB issued ASU No. 2011-08: Intangibles – Goodwill and Other (Topic 350) – Testing Goodwill for Impairment. The update simplifies how a company tests goodwill for impairment by allowing both public and nonpublic entities the option to first assess qualitative factors to determine whether it is necessary to perform the two-step quantitative goodwill impairment test. Under that option, an entity would no longer be required to calculate the fair value of a reporting unit unless the entity determines, based on a qualitative assessment, that it is more likely than not that its fair value is less than its carrying amount. The update is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011. Early adoption is permitted. The Company does not anticipate that the adoption of this update will have a material impact on its consolidated financial statements.

### Item 3. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to market risk from changes in foreign currency exchange rates and, to a much lesser extent, interest rates on investments in short-term instruments, which could impact our results of operations and financial position. We do not currently engage in any hedging or market risk management tools. There have been no material changes with respect to market risk previously disclosed in our Annual Report on Form 10-K for our 2011 fiscal year.

#### *Foreign Currency Exchange Rate Risk*

The financial reporting of our non-U.S. subsidiaries is denominated in currencies other than the U.S. dollar. Since the functional currency of our non-U.S. subsidiaries is the local currency, foreign currency translation adjustments are accumulated as a component of accumulated other comprehensive income in stockholders' equity. Assuming a hypothetical aggregate change of 10% in the exchange rates of foreign currencies against the U.S. dollar at October 31, 2011, our assets and liabilities would increase or decrease by \$2.0 million and \$0.9 million, respectively, and our net sales and net (loss) or earnings would increase or decrease by \$1.5 million and \$0.1 million, respectively, on an annual basis.

We also maintain intercompany balances and loans receivable with subsidiaries with different local currencies. These amounts are at risk of foreign exchange losses if exchange rates fluctuate. Assuming a hypothetical aggregate change of 10% in the exchange rates of foreign currencies against the U.S. dollar at October 31, 2011, our pre-tax earnings would be favorably or unfavorably impacted by approximately \$0.3 million, on an annual basis.

#### *Interest Rate Risk*

Our excess cash is invested in highly liquid short term money market funds and short term investments in U.S. Treasury bills. Changes in interest rates may affect the investment income we earn on money market funds and short term investments and therefore affect our cash flows and results of operations. As of October 31, 2011, we were exposed to interest rate change market risk with respect to our money market accounts and short term investments totaling \$14.2 million. The money market accounts and short-term investments yield or bear interest rates ranging from 0% to 0.05%. As of October 31, 2011, based on the investments held, it is determined we have no material interest rate risk.

As of October 31, 2011, we have fixed interest rate financing on transportation and equipment leases.

### Item 4. Controls and Procedures

#### (a) Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, the Company's management conducted an evaluation (as required under Rules 13a-15(b) and 15d-15(b) under the Securities Exchange Act of 1934, as amended (the Exchange Act)) of the Company's disclosure controls and procedures (as such term is defined under the Exchange Act), under the supervision and with the participation of the principal executive officer and the principal financial officer. Based on this evaluation, the principal executive officer and the principal financial officer concluded that the Company's disclosure controls and procedures are effective as of the end of the period covered by this report. Notwithstanding the foregoing, a control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that it will detect or uncover failures within the Company to disclose material information otherwise required to be set forth in the Company's periodic reports.

#### (b) Changes in Internal Controls over Financial Reporting

There was no change in the Company's internal controls over financial reporting during the fiscal quarter covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.



**PART II OTHER INFORMATION**

Item 1. Legal Proceedings

There have been no other material developments with respect to previously reported legal proceedings discussed in the annual report on Form 10-K for the fiscal year ended July 31, 2011 filed with the Securities and Exchange Commission. See Note 13.

Item 1A. Risk Factors

There have been no material changes from the risk factors disclosed in Part 1, Item 1, of the Company's Annual Report on Form 10-K for the fiscal year ended July 31, 2011.

Item 6. Exhibits

| <u>Exhibit No.</u> | <u>Exhibit</u>  |
|--------------------|---|
| 31.1               | Certification of Elazar Rabbani, Ph.D. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.   |
| 31.2               | Certification of Barry Weiner pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.  |
| 32.1               | Certification of Elazar Rabbani, Ph.D. pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 32.2               | Certification of Barry Weiner pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.          |
| 101.INS*           | XBRL Instance Document  |
| 101.SCH*           | XBRL Taxonomy Extension Schema Document   |
| 101.CAL*           | XBRL Taxonomy Extension Calculation Linkbase Document   |
| 101.DEF*           | XBRL Taxonomy Extension Definitions Linkbase Document   |
| 101.LAB*           | XBRL Taxonomy Extension Label Linkbase Document   |
| 101.PRE*           | XBRL Taxonomy Extension Presentation Linkbase Document  |

\*XBRL (Extensible Business Reporting Language) information is being furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ENZO BIOCHEM, INC.

(Registrant)

Date: December 12, 2011

by: /s/ Barry Weiner

Chief Financial Officer, Principal Accounting Officer,  
Treasurer and Director